López-Álvarez, Marina
Heuker, Marjolein
Sjollema, Klaas A.
van Dam, Gooitzen M.
van Dijl, Jan Maarten
IJpma, Frank F. A.
van Oosten, Marleen
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (713660)
Graduate School of Medical Sciences of the University of Groningen
Article History
Received: 25 September 2021
Accepted: 19 January 2022
First Online: 26 January 2022
Declarations
:
: Permission for this study was granted by the local Medical Ethical Review Board (Medisch Ethische Toetsingscommissie; METc; number 2016/481) for the use of surplus osteosynthesis devices and clinical data that would not interfere with the diagnostic process. The research was performed with adherence to the guidelines of the Declaration of Helsinki.
: Patients gave informed consent, which included the use of pseudoanonymized data and samples for the purpose of research and publication.
: All authors have read the manuscript and agree with its publication.
: GMvD is a consultant for OncoNano Medicine Inc. and CEO, founder, and shareholder of the AxelaRx/TRACER BV group. The other authors have no conflicts of interest to disclose.